HURA vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 03, 2026

HURA

39.7
AI Score
VS
CBIO Wins

CBIO

58.4
AI Score

Investment Advisor Scores

HURA

40score
Recommendation
SELL

CBIO

58score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric HURA CBIO Winner
Net Income -7.54M -48.12M HURA
ROE -32.5% -29.5% CBIO
ROA -25.4% -26.3% HURA
Total Assets 29.70M 182.76M CBIO
Cash 6.30M 171.59M CBIO
Current Ratio 1.15 9.66 CBIO
Free Cash Flow -4.46M -28.56M HURA

Relative Price Performance (Last 90 Days)

HURA 1M: -8.6% · 3M: -19.1% CBIO 1M: -22.8% · 3M: -15.6%

Current Technical Phase

HURA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 37

RSI (14): 36.6 · Price: $1.91

CBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 36

RSI (14): 35.6 · Price: $14.32

Fundamentals Snapshot

Metric HURA CBIO
Market Cap — —
Forward P/E -4.4 -5.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin — 1.0%
Operating Margin 0.0% -14.3%
EPS -0.51 -0.14
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CBIO is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.